Ibrutinib has been selected for Medicare price negotiation under the Inflation Reduction Act. The authors summarize the House Oversight Committee investigation to be considered by CMS during the price negotiation process.
Jason B. Gibbons, PhD
Advertisement
Articles by Jason B. Gibbons, PhD
The authors review a House Oversight Committee investigation report on AbbVie’s practices pertaining to adalimumab (Humira) to shed light on broader pharmaceutical market dynamics hindering a competitive market.
Medicare beneficiaries attributed to small practices in accountable care organizations (ACOs) achieve greater savings than beneficiaries attributed to large practices in ACOs.
Advertisement
Latest Updated Articles
- Small Practice Participation and Performance in Medicare Accountable Care Organizations
Published: March 11th 2022 | Updated:
Adjusting Starting Points for Initial Price Offers: The Example of IbrutinibPublished: April 2nd 2024 | Updated:
- Humira: The First $20 Billion Drug
Published: February 8th 2023 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Telemedicine Boosts Quality of Life, Inhaler Technique for Severe COPD
2
A "One-Two Punch" to Innovation? The Most Favored Nation Order and Broader US Drug Pricing Reform
3
Bispecific Antibodies in Multiple Myeloma Are Moving From Clinical Trials to Community Practice
4
Physician Peer Influence Drives Uptake of Opportunistic Salpingectomy for Ovarian Cancer Prevention
5
